全文获取类型
收费全文 | 23424篇 |
免费 | 1416篇 |
国内免费 | 172篇 |
专业分类
耳鼻咽喉 | 294篇 |
儿科学 | 610篇 |
妇产科学 | 799篇 |
基础医学 | 2674篇 |
口腔科学 | 731篇 |
临床医学 | 1995篇 |
内科学 | 4550篇 |
皮肤病学 | 539篇 |
神经病学 | 1085篇 |
特种医学 | 857篇 |
外国民族医学 | 11篇 |
外科学 | 4153篇 |
综合类 | 413篇 |
现状与发展 | 2篇 |
一般理论 | 14篇 |
预防医学 | 1952篇 |
眼科学 | 617篇 |
药学 | 2203篇 |
中国医学 | 170篇 |
肿瘤学 | 1343篇 |
出版年
2023年 | 256篇 |
2022年 | 754篇 |
2021年 | 1301篇 |
2020年 | 729篇 |
2019年 | 920篇 |
2018年 | 1228篇 |
2017年 | 765篇 |
2016年 | 796篇 |
2015年 | 826篇 |
2014年 | 1162篇 |
2013年 | 1347篇 |
2012年 | 1937篇 |
2011年 | 2076篇 |
2010年 | 1181篇 |
2009年 | 867篇 |
2008年 | 1218篇 |
2007年 | 1195篇 |
2006年 | 1087篇 |
2005年 | 1033篇 |
2004年 | 881篇 |
2003年 | 806篇 |
2002年 | 714篇 |
2001年 | 175篇 |
2000年 | 152篇 |
1999年 | 133篇 |
1998年 | 98篇 |
1997年 | 95篇 |
1996年 | 98篇 |
1995年 | 84篇 |
1994年 | 72篇 |
1993年 | 67篇 |
1992年 | 65篇 |
1991年 | 77篇 |
1990年 | 78篇 |
1989年 | 64篇 |
1988年 | 62篇 |
1987年 | 72篇 |
1986年 | 62篇 |
1985年 | 51篇 |
1984年 | 47篇 |
1983年 | 46篇 |
1982年 | 41篇 |
1981年 | 30篇 |
1980年 | 30篇 |
1978年 | 21篇 |
1977年 | 17篇 |
1976年 | 20篇 |
1973年 | 19篇 |
1971年 | 16篇 |
1966年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections
下载免费PDF全文
![点击此处可从《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Morteza Abkar Jafar Amani Abbas Sahebghadam Lotfi Gholamreza Nikbakht Brujeni Saeed Alamian Mehdi Kamali 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(8):667-675
Brucellosis is a world prevalent endemic illness that is transmitted from domestic animals to humans. Brucella spp. exploits urease for survival in the harsh conditions of stomach during the gastrointestinal infection. In this study, we examined the immune response and the protection elicited by using recombinant Brucella urease (rUrease) vaccination in BALB/c mice. The urease gene was cloned in pET28a and the resulting recombinant protein was employed as subunit vaccine. Recombinant protein was administered subcutaneously and intraperitoneally. Dosage reduction was observed with subcutaneous (SC) vaccination when compared with intraperitoneal (IP) vaccination. rUrease induced mixed Th1–Th2 immune responses with high titers of specific IgG1 and IgG2a. In lymphocyte proliferation assay, splenocytes from IP and SC‐vaccinated mice displayed a strong recall proliferative response with high amounts of IL‐4, IL‐12 and IFN‐γ production. Vaccinated mice were challenged with virulent Brucella melitensis, B. abortus and B. suis. The SC vaccination route exhibited a higher degree of protection than IP vaccination (p value ≤ 0.05). Altogether, our results indicated that rUrease could be a useful antigen candidate for the development of subunit vaccines against brucellosis. 相似文献
4.
Josh Greenstein Devjani Das Josie Acuna Monica Kapoor Cara Brown Abbas Husain Brendan Lally Barry Hahn 《The American journal of emergency medicine》2019,37(2):313-316
Background
In the emergency department, rib fractures are a common finding in patients who sustain chest trauma. Rib fractures may be a sign of significant, underlying pathology, especially in the elderly patients where rib fractures are associated with significant morbidity and mortality. To date, no studies have evaluated the ability of ultrasound to detect rib fractures using cadaver models and subsequently use this model as a teaching tool.Objectives
The purpose of this study was to determine if it is possible to generate rib fractures on cadaver models which could be accurately identified using ultrasound.Methods
This was a cross-sectional study performed during one session at a cadaver lab. A single hemithorax from four adult cadavers were used as models. Single rib fractures on each of rib five through eight were created. Four subjects, blinded to the normal versus fractured ribs, were asked to identify the presence of a fracture on each rib.Results
A total of 8 of 16 potential ribs had fractured induced by study staff. Mean accuracy was 55% for all subjects. The overall sensitivity and specificity for detecting rib fractures was 50% (CI: 31.89–68.11) and 59.38% (CI: 35.69–73.55) respectively. The overall PPV and NPV was 55.17% and 54.29% respectively.Conclusions
In this pilot study, subjects were not able to detect induced rib fractures using ultrasound on cadaver models. The use of this model as a teaching tool in the detection of rib fractures requires further investigation. 相似文献5.
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma
6.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献7.
8.
9.
10.
Introduction: Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas of skin-homing T-cells that initially or mainly manifest cutaneously. Treatment of CTCL is challenging given the disease states’ varying presentation and prognosis. Systemic treatment options often lack comparative evidence and have relatively low response rates and short duration of response. The recent Food and Drug Administration (FDA) approval of mogamulizumab in adult patients with relapsed or refractory (R/R) CTCL after at least one prior line of therapy provided a new treatment option to patients with advanced disease.
Areas covered: The authors discuss basic information about CTCL and mogamulizumab’s mechanism of action. Then, the authors discuss the agent’s efficacy. Finally, the authors evaluate the safety of mogamulizumab in comparison to other agents available in CTCL.
Expert opinion: Mogamulizumab has been shown to be an effective and well tolerated therapy for patients with relapsed and refractory MF/SS with excellent activity in the circulating component of the disease. 相似文献